Recently, VERIGRAFT presented their technology and ongoing clinical trial at the American Venous Forum 2025 in Atlanta, Georgia. Our Chief Medical Officer, Jan Holgersson, and our Principal Investigator, Andrés Garciá Léon were extremely pleased with the days in Atlanta;
“It has been a top-tier event where the vascular community has had the opportunity to discuss not only current therapies and advancements but also future developments that could enhance the quality of life for patients with venous diseases”, says Andrés García Léon, Head of Angiology and Vascular Surgery at Virgen de Valme University Hospital, Associate Professor of the University of Seville and VERIGRAFTs Principal Investigator in the TECVI-1 trial. “The networking opportunities have been outstanding, and the preliminary results of the TECVI-1 study have generated great anticipation, the vascular community eagerly awaits the final results in the near future”, he continues.
We look forward to sharing more updates as our research progresses and remain committed to advancing the future of cardiovascular medicine. Stay informed by following our latest developments.